These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17105601)

  • 21. Hepatitis B virus DNA in serum of 'anti-HBc only'-positive healthy Lebanese blood donors: significance and possible implications.
    El-Zaatari M; Kazma H; Naboulsi-Majzoub M; Haidar M; Ramlawi F; Mahfoud Z; Ramia S
    J Hosp Infect; 2007 Jul; 66(3):278-82. PubMed ID: 17540476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not.
    Stramer SL
    Transfusion; 2005 Aug; 45(8):1242-6. PubMed ID: 16078908
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatitis A virus prevalence in plasma donations.
    Weimer T; Streichert S; Watson C; Gröner A
    J Med Virol; 2002 Aug; 67(4):469-71. PubMed ID: 12115990
    [No Abstract]   [Full Text] [Related]  

  • 24. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT.
    Brojer E; Grabarczyk P; Liszewski G; Mikulska M; Allain JP; Letowska M;
    Hepatology; 2006 Dec; 44(6):1666-74. PubMed ID: 17133474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective "in-house" real-time PCR assay.
    Daniel HD; Fletcher JG; Chandy GM; Abraham P
    Indian J Med Microbiol; 2009; 27(2):111-5. PubMed ID: 19384032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus infection in blood donors: to screen or not to screen?
    Anand AC; Dhot PS; Ohri VC
    Natl Med J India; 1997; 10(6):304-5. PubMed ID: 9481109
    [No Abstract]   [Full Text] [Related]  

  • 27. Occult hepatitis B infection in blood donors.
    Reesink HW; Engelfriet CP; Henn G; Mayr WR; Delage G; Bernier F; Krusius T; Assal A; Gallian P; Corbi C; Morel P; David B; De Micco P; Murokawa H; Yugi H; Hino S; Tadokoro K; Flesland O; Brojer E; Letowska M; Olim G; Nascimento F; Gonçalves H; Castro L; Morais M; Stezinar SL; Alvarez M; Sauleda S; González R; Niederhauser C; Stolz M; Allain JP; Owusu-Ofori S; Eglin R; Stramer S; Busch M; Strong DM; Epstein J; Biswas R
    Vox Sang; 2008 Feb; 94(2):153-66. PubMed ID: 18205672
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of the Roche cobas s 201 system and cobas TaqScreen multiplex test for blood screening: a European multicenter study.
    Jarvis L; Becker J; Tender A; Cleland A; Queiros L; Aquiar A; Azevedo J; Aprili G; Bressan F; Torres P; Nieto S; Ursitti A; Montoro J; Vila E; Ramada C; Saldanha J
    Transfusion; 2008 Sep; 48(9):1853-61. PubMed ID: 18513254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The German experience with NAT.
    Roth WK; Seifried E
    Transfus Med; 2002 Aug; 12(4):255-8. PubMed ID: 12220254
    [No Abstract]   [Full Text] [Related]  

  • 30. NAT screening of blood and plasma donations: evolution of technology and regulatory policy.
    Tabor E; Epstein JS
    Transfusion; 2002 Sep; 42(9):1230-7. PubMed ID: 12430684
    [No Abstract]   [Full Text] [Related]  

  • 31. [Study about seroconversion of HBV NAT screening-positive crowd from blood donors].
    Wang DW; Wang TB; Liu FP; Shi LL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):127-9. PubMed ID: 18574536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral diagnostics in the arena of blood donor screening.
    Stramer SL
    Vox Sang; 2004 Jul; 87 Suppl 2():180-3. PubMed ID: 15209912
    [No Abstract]   [Full Text] [Related]  

  • 33. [Australia antigen and detection of hepatic diseases in a population of blood donors. Clinical and biological study. Biological supervision of transfused patients].
    Migeotte P; Otto-Servais M; Brocteur J; Plomteux G; Ruyters L; Heusghem C; André A
    Arch Fr Mal App Dig; 1971 Dec; 60(12):637-48. PubMed ID: 5158153
    [No Abstract]   [Full Text] [Related]  

  • 34. A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period.
    Wendel S; Levi JE; Biagini S; Candotti D; Allain JP
    Transfusion; 2008 Aug; 48(8):1602-8. PubMed ID: 18466175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors.
    Dettori S; Candido A; Kondili LA; Chionne P; Taffon S; Genovese D; Iudicone P; Miceli M; Rapicetta M
    J Infect; 2009 Aug; 59(2):128-33. PubMed ID: 19586663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. US FDA approves a new blood screening test for HIV and hepatitis B and C.
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):5. PubMed ID: 19622052
    [No Abstract]   [Full Text] [Related]  

  • 37. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion.
    Inaba S; Ito A; Miyata Y; Ishii H; Kajimoto S; Tanaka M; Maruta A; Saito S; Yugi H; Hino M; Tadokoro K
    Transfusion; 2006 Nov; 46(11):2028-9. PubMed ID: 17076860
    [No Abstract]   [Full Text] [Related]  

  • 39. [Distribution of the Australia antigen in a group of blood donors from Genoa].
    Burlando L; Avanzi G
    Pathologica; 1970; 62(914):235-9. PubMed ID: 5524904
    [No Abstract]   [Full Text] [Related]  

  • 40. Safe blood transfusion practices in blood banks of Karachi, Pakistan.
    Kassi M; Afghan AK; Khanani MR; Khan IA; Ali SH
    Transfus Med; 2011 Feb; 21(1):57-62. PubMed ID: 21029219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.